

FOI REF: 26/032

Eastbourne District General Hospital

Kings Drive  
Eastbourne  
East Sussex  
BN21 2UD

28<sup>th</sup> January 2026

Tel: 0300 131 4500  
Website: [www.esht.nhs.uk](http://www.esht.nhs.uk)

## FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

**Q1. How many patients who have a current diagnosis of Multiple Sclerosis received treatment in the last six months with any of the following treatment regimens (July 2025 – December 2025)?**

• Ocrevus (ocrelizumab) IV (300mg/30ml)	0
• Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)	0
• Kesimpta (ofatumumab)	0
• Briumvi (ublituximab)	0
• Mavenclad (cladribine)	0
• Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	3
• Natalizumab (Tysabri and Tyruko)	0

**Q1a. Of the patients identified in question one, how many patients received the same treatment in the previous six-month period? (i.e. How many of the same patients received treatment with each treatment regimen in January 2025 to June 2025 AND July 2025 – December 2025?)**

• Ocrevus (ocrelizumab) IV (300mg/30ml)	0
• Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)	0
• Kesimpta (ofatumumab)	0
• Briumvi (ublituximab)	0
• Mavenclad (cladribine)	0
• Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	35
• Natalizumab (Tysabri and Tyruko)	0

**Q2. How many patients have received a new diagnosis for Multiple Sclerosis in the latest six-month period (July 2025 – December 2025)?**

4

Cont.../

**Q2a. Of the patients identified in question two, how many of these patients have received any of the following treatment regimens as their first treatment following their Multiple Sclerosis diagnosis?**

• <b>Ocrevus (ocrelizumab) IV (300mg/30ml)</b>	0
• <b>Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)</b>	0
• <b>Kesimpta (ofatumumab)</b>	0
• <b>Briumvi (ublituximab)</b>	0
• <b>Mavenclad (cladribine)</b>	0
• <b>Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)</b>	0
• <b>Natalizumab (Tysabri and Tyruko)</b>	0

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department ([esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department  
[esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)